Yoda Therapeutics Begins Phase 2 Trial for MSA Treatment

Yoda Therapeutics Inc. has dosed the first patient in its Phase 2 trial of YA-101 for Multiple System Atrophy (MSA), announced in a press release. MSA is a rare and rapidly progressing neurodegenerative disorder that severely impacts motor functions and autonomic systems.

YA-101, a novel chemical entity, aims to treat neurodegenerative diseases by inhibiting neuroinflammation and enhancing neural plasticity. The Phase 2 trial will assess the safety, tolerability, pharmacokinetics, and efficacy of YA-101 in MSA patients across multiple sites in the United States and Taiwan. This trial follows the successful completion of Phase 1 trials in Australia, which focused on safety and tolerability in healthy volunteers.

The trial is designed as a randomized, double-blind, placebo-controlled study, targeting MSA patients with walking ability, including those requiring assistance. Comprehensive assessments will be conducted through clinical symptoms, biomarkers, and imaging.